
Igor Puzanov, MD, MSCI, FACP, discusses the adverse effects associated with immunotherapy and how to manage them.

Igor Puzanov, MD, MSCI, FACP, discusses the adverse effects associated with immunotherapy and how to manage them.

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

The utilization of monoclonal antibodies such as nivolumab and Ipilimumab have become vital in shifting the treatment paradigm in gastroesophageal and gastrointestinal cancers.

Dhyan Chandra, PhD, discusses recent findings relating to low levels of cytochrome C in Black men with prostate cancer, plus plans for future research on this topic.

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

Dhyan Chandra, PhD, discusses the need for resources to evaluate racial disparities in prostate cancer.

Neoadjuvant chemosensitivity was associated with an improvement in overall survival following adjuvant chemotherapy in patients with resectable gastric cancer, according to findings from a cohort study that were published in JAMA Network Open.

Anna Woloszynska, PhD, discusses continued research efforts investigating racial disparities in prostate cancer.

The combination of tivozanib and durvalumab showcased early efficacy with a manageable safety profile in patients with previously untreated advanced hepatocellular carcinoma.

Nathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.

Dhyan Chandra, PhD, discusses evaluating biological differences between African American and Caucasian men with prostate cancer.

Dhyan Chandra, PhD, discusses the potential to assess mitochondrial function to inform outcomes in prostate cancer.

Anna Woloszynska, PhD, discusses the need to assess biological factors of racial disparities in prostate cancer.

New grants from the U.S. Department of Defense and American Cancer Society will fund work by two Roswell Park Comprehensive Cancer Center teams focused on understanding and eliminating prostate cancer health disparities.

Nathaniel Ivanick, MD, FCCP, discusses the evolution of interventional pulmonology, the benefits of robotic navigational bronchoscopy and other novel technologies in the field, and ongoing research that could further push the paradigm forward.

Nathaniel Ivanick, MD, FCCP, discusses the role of interventional pulmonologists in advanced diagnostics in lung cancer.

Following a national search, Roswell Park Comprehensive Cancer Center has promoted Emese Zsiros, MD, PhD, FACOG, to lead its Department of Gynecologic Oncology.

Nathaniel Ivanick, MD, FCCP, discusses advancements in interventional pulmonology.

Jamie Smith, EdD, MLS, has joined the cancer center as Chief Academic Officer, Senior Vice President of Education and Dean of the Roswell Park Graduate Division of the University at Buffalo.

Driven to move the mission of Roswell Park Comprehensive Cancer Center forward despite the many challenges the COVID-19 pandemic brought with it, Roswell Park President and CEO Candace S. Johnson, PhD, has marked a year of unprecedented success in faculty recruitment

Teams of researchers from Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center are combining efforts after together securing a nearly $9 million grant from the National Cancer Institute to develop new and better treatments for ovarian cancer.

Anurag Singh, MD, discussed the potential advantage to treating patients with radiation therapy at specific times of day, how the utilization of prophylactic gabapentin has decreased the need for narcotics in managing oral mucositis in patients with head and neck cancer, and the potential use of single-fraction radiation therapy in oncology.

Anurag Singh, MD, discusses the potential effects of radiation timing in head and neck cancer.

The FDA approval of the first chimeric antigen receptor T-cell therapy in March 2021 for the treatment of relapsed/refractory multiple myeloma represents a significant advance.

American Nurses Credentialing Center gives nod of distinction to popular program.

One of the most influential and accomplished figures in the field of cancer immunotherapy has returned to his Western New York roots to take on leadership roles in both research and clinical care at Roswell Park Comprehensive Cancer Center.

The method used to calculate how obesity is measured may impact whether it should be considered as a risk factor for non–small cell lung cancer.

Eunice Wang, MD, discusses the KOMET-001 trial, the potential for KO-539 to address an unmet need in acute myeloid leukemia, and the future of menin inhibition in this disease.

Those diagnosed with von Hippel-Lindau disease have a resource for that complete and coordinated care in Roswell Park Comprehensive Cancer Center, which was recently named a VHL Clinical Care Center by the VHL Alliance.